Multiple Myeloma CAR-T in China: Approved and Trial Options
- MedBridgeNZ
- 54 minutes ago
- 10 min read
By MedBridgeNZ | Last updated: August 2026
Key Takeaways
Conditional BCMA Approvals: China’s National Medical Products Administration (NMPA) has conditionally approved several autologous BCMA-directed CAR-T products for specified adults with relapsed or refractory multiple myeloma after prior treatment.
Alternative Antigen Targeting: For patients experiencing disease progression after BCMA-targeted therapy, investigational GPRC5D CAR-T constructs are actively being evaluated within clinical trial settings at specialized Chinese hematology institutions.
Investigational Dual-Target Platforms: Clinical studies are assessing tandem and bicistronic BCMA/GPRC5D CAR-T therapies designed to address single-antigen loss; trial phase and enrollment status vary by protocol.
Records for Hospital Review: Hospitals commonly request longitudinal pathology, laboratory, imaging, and treatment records. Exact requirements—including whether antigen testing or additional organ-function studies are needed—vary by product, trial protocol, and institution.
Quick Answer
Multiple myeloma CAR-T in China encompasses conditionally approved BCMA-directed autologous therapies alongside investigational clinical trials targeting alternative antigens, such as GPRC5D, and dual-target BCMA/GPRC5D constructs.
Approved BCMA CAR-T: Access to NMPA-approved products exists, but access depends on hospital acceptance, product capacity, and case-specific clinical review.
Investigational GPRC5D CAR-T: Academic clinical trials evaluating GPRC5D targets. Some protocols include patients previously exposed to BCMA-directed therapy, but prior-treatment and antigen-expression requirements vary by trial.
Dual-Target Constructs: Investigational studies evaluating simultaneous BCMA and GPRC5D targeting to reduce immune escape.
International Record Review: Where offered, medical records may be submitted to a hospital review channel before travel. This preliminary review does not confirm treatment eligibility, trial enrollment, or admission.
Institutional eligibility and admission depend strictly on protocol-specific clinical criteria, baseline organ fitness, and scheduling availability at designated tertiary hematology departments.
What Options Are Considered When Multiple Myeloma Relapses After Standard Drug Classes?
The management of multiple myeloma has advanced significantly with the integration of proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies. However, patients who develop disease refractory to these core drug classes—termed triple-class refractory—face limited conventional treatment options and historically shortened progression-free intervals.
When drug therapy no longer provides durable disease control, treating hematologists may discuss several next-line options. This article examines only BCMA, GPRC5D, and BCMA/GPRC5D CAR-T pathways; it is not a complete treatment algorithm and does not cover all available drug, antibody, transplant, or clinical-trial options:
Conditionally Approved CAR-T Pathway: BCMA-directed CAR-T for patients who meet the applicable product label and hospital criteria.
Investigational CAR-T Pathways: GPRC5D or BCMA/GPRC5D constructs available only under applicable research protocols.
For international families exploring multiple myeloma CAR-T in China, distinguishing between conditionally approved therapies and investigational trials is essential for informed cross-border care planning. Navigating these medical channels requires rigorous document preparation, accurate medical translation of specialized hematology records, and direct institutional communication.
How Does BCMA-Directed CAR-T Function in Relapsed Multiple Myeloma?
B-cell maturation antigen (BCMA), predominantly expressed on plasmablasts, normal plasma cells, and malignant plasma cells, represents the most established target in multiple myeloma cellular therapy.
Definition: BCMA CAR-T is an autologous cellular therapy wherein a patient’s extracted T cells are genetically modified via a viral vector to express a chimeric antigen receptor specific to the BCMA protein.
Function: Upon reinfusion following lymphodepleting chemotherapy, these engineered cells bind directly to BCMA-expressing cells, initiating targeted cytotoxic cell lysis independent of major histocompatibility complex (MHC) presentation.
Typical Use Case: Indicated for specific adult patients with relapsed or refractory multiple myeloma who have received multiple prior lines of therapy—typically including a proteasome inhibitor and an immunomodulatory agent—and have demonstrated disease progression.
Why This Matters: For international patients, conditionally approved options provide a standardized, regulatory-backed pathway outside of trial-only environments. Understanding these distinctions is critical for care planning; for a detailed comparison of access requirements, read our complete guide on Commercial CAR-T vs Clinical Trials in China.
Evidence Snapshot:
Source: FUMANBA-1 nonrandomized clinical trial of equecabtagene autoleucel
Study Type: Multicenter, single-arm phase 1b/2 clinical trial
Reported Finding: Among 101 efficacy-evaluable patients, the reported overall response rate was 96.0% at a median follow-up of 13.8 months. Results apply to this specific study population and should not be compared directly with outcomes from other CAR-T products.
What Is GPRC5D and Why Is It Targeted After BCMA Therapy?
While BCMA-directed CAR-T yields high initial response rates, a subset of patients experience relapse due to BCMA antigen down-regulation, antigen loss, or limited persistence of engineered T cells. This clinical challenge has driven the development of therapies targeting alternative, non-overlapping plasma cell antigens.
GPRC5D is expressed on malignant and normal plasma cells, while expression in other normal tissues is largely associated with keratinized structures such as hair follicles. This distribution is relevant to the skin, nail, and taste-related adverse effects reported with some GPRC5D-directed therapies.
Mechanism of Action: GPRC5D CAR-T cells bind specifically to GPRC5D receptors on malignant plasma cells, mediating targeted destruction regardless of whether the target cell expresses BCMA.
Clinical Relevance: Because GPRC5D expression is independent of BCMA, GPRC5D-directed CAR-T is being investigated as an alternative targeting mechanism for patients who have relapsed following anti-BCMA CAR-T or BCMA-directed bispecific antibodies. Patients facing this specific clinical challenge can explore further in our dedicated overview: CAR-T After CAR-T Relapse: Can Another Cellular Therapy Be Explored in China?
What Is the Role of Investigational BCMA/GPRC5D Dual-Target CAR-T?
Dual-target CAR-T constructs—engineered to bind both BCMA and GPRC5D simultaneously or via bicistronic/tandem vector designs—are currently under clinical investigation in specialized Chinese academic centers.
Definition: Dual-target CAR-T utilizes autologous T cells engineered with dual binding domains designed to recognize either BCMA, GPRC5D, or both antigens simultaneously on the surface of multiple myeloma cells.
Function: In constructs designed to recognize either antigen, dual targeting aims to make escape through loss of a single antigen less likely. Whether this strategy improves response durability remains under clinical investigation.
Typical Use Case: Investigated in protocol-eligible patients with relapsed or refractory multiple myeloma. Prior-treatment, disease-burden, cytogenetic, organ-function, and antigen requirements vary by trial.
Why This Matters: Dual-target constructs represent an investigational frontier in cellular hematology. Dual-target approaches in China remain under investigational protocols and are not commercially approved products. Since access to these early-phase protocols is restricted to specific academic centers, we recommend reviewing our Guide to Choosing a CAR-T Hospital in China (Public vs. Private) to understand how facility capabilities impact trial enrollment.
How Do Approved and Investigational Multiple Myeloma CAR-T Options Compare in China?
Understanding whether a treatment pathway represents a conditionally approved product or a trial protocol is critical for international patients evaluating medical coordination. The following comparison covers only the CAR-T pathways discussed in this article. It is not a complete treatment algorithm for relapsed multiple myeloma.
Target / Construct | Regulatory Status in China | Typical Clinical Context | Key Logistical & Clinical Considerations |
BCMA CAR-T (e.g., Equecabtagene autoleucel, Zevorcabtagene autoleucel, Ciltacabtagene autoleucel) | Conditionally Approved (NMPA) | Adults with relapsed or refractory multiple myeloma after at least three prior lines, including a PI and an IMiD, for the listed NMPA-approved examples. | Product availability, apheresis and manufacturing capacity, hospital acceptance, and total treatment costs vary by institution and case. |
GPRC5D CAR-T | Investigational (Clinical Trial) | Relapsed/refractory MM; post-BCMA relapse; dual-refractory status. | Strict trial-specific inclusion criteria; limited enrollment slots; protocol-defined toxicity monitoring. |
BCMA / GPRC5D Dual-Target | Investigational | Heavily pretreated MM with high risk of single-antigen escape. | Trial phase and enrollment status vary by protocol; requires rigorous pre-screening. |
What Clinical Risks and Monitoring Protocols Apply to Myeloma CAR-T?
CAR-T cell therapy carries specific, well-characterized physiological risks that typically require care at specialized tertiary medical centers equipped with CAR-T toxicity monitoring, management, and escalated care capabilities.
Cytokine Release Syndrome (CRS): A systemic inflammatory response triggered by rapid T-cell proliferation and cytokine elevation. Manifestations range from low-grade fevers to hypotension, hypoxia, and multi-organ dysfunction. Management may include tocilizumab and/or corticosteroids, depending on clinical severity and institutional protocol.
Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS): Central nervous system toxicity presenting as word-finding difficulty, confusion, tremors, or somnolence, requiring frequent neurological assessments.
Cytopenias and Infection Risks: Prolonged neutropenia, thrombocytopenia, and hypogammaglobulinemia are frequent following lymphodepletion and cellular infusion, necessitating prophylactic anti-infective regimens and blood product support.
Target-Specific Effects: As noted, GPRC5D-directed approaches require dermatological and nutritional support for managed epithelial and taste alterations.
Institutional protocols commonly require structured inpatient observation during and immediately following the infusion window. Additional local monitoring may be required before the treating team considers international travel appropriate. Patients should discuss product-specific risks, alternatives, and travel fitness with their treating hematologist before making cross-border plans.
Representative Administrative Pathway: Coordinating Multiple Myeloma CAR-T in China
The following pathway is illustrative and outlines administrative routing; it does not describe a specific MedBridgeNZ patient.
Clinical Context: An adult patient with relapsed multiple myeloma, previously treated with standard pharmacological therapies, explores alternative cellular therapy options after disease recurrence.
Records Prepared for Review: The patient’s care team compiles comprehensive documentation, including serial serum protein electrophoresis (SPEP), serum free light chain (sFLC) ratios, recent bone marrow aspirate reports, cytogenetic FISH reports, baseline imaging scans, and a detailed prior treatment history.
Institutional Review Channel: MedBridgeNZ formats and translates the medical dossier into standardized bilingual formats, routing the file to designated tertiary academic hematology departments in China for a preliminary, non-binding record review.
Possible Discussion Points for the Treating Oncologist: The patient discusses the institutional assessment with their local oncologist, reviewing whether either pathway warrants further specialist assessment, together with other treatment alternatives and any need for bridging therapy.
Administrative Next Steps: Upon the patient's decision to proceed, MedBridgeNZ coordinates administrative logistics, facilitates China medical travel and visa requirements where applicable, and organizes bilingual on-site accompaniment for the duration of the institutional stay.
Please note: Individual medical outcomes vary significantly depending on baseline health, prior treatments, and specific disease progression.
What Records Should an International Multiple Myeloma Patient Prepare?
Accurate institutional assessment by Chinese tertiary hematology centers depends entirely on the completeness of longitudinal clinical documentation. Hospitals commonly request some or all of the following records. Exact requirements depend on the product, trial protocol, and receiving institution:
Bone Marrow Pathology: Detailed aspirate and core biopsy reports, flow cytometry immunophenotyping, and quantitative plasma cell percentage.
Cytogenetic / FISH Profiles: Comprehensive fluorescence in situ hybridization (FISH) panels detailing standard and high-risk cytogenetic markers.
Longitudinal Paraprotein Metrics: Serial SPEP results, immunofixation electrophoresis (IFE), and serial paraprotein measurements demonstrating disease kinetics.
Treatment Chronology: Comprehensive documentation of all prior regimens, exact drug combinations, cycles completed, best response achieved, and documented dates of disease progressionfgffgfgfgfg
Imaging & Organ Function: Recent imaging, such as whole-body low-dose CT, PET-CT, or MRI, together with requested hematology and organ-function tests. Echocardiography or pulmonary function testing may be requested depending on the applicable protocol.
Administrative Submission Note: Large imaging files may need to be transferred through an access-controlled method accepted by the receiving hospital. Patients should confirm the approved transfer channel before uploading identifiable medical records. Upon receipt of initial files, a Consultation Preparation Form is often utilized to gather targeted clinical histories, ensuring the finalized dossier aligns with the intake standards of Chinese tertiary hematology departments.
For further actionable steps, review exactly What Records You Need for CAR-T Pre-Screening in China and understand how receiving facilities formulate a China Hospital Treatment Cost Estimate.
Frequently Asked Questions
Are any BCMA CAR-T products NMPA-approved for multiple myeloma in China?
Yes. The NMPA has conditionally approved equecabtagene autoleucel, zevorcabtagene autoleucel, and ciltacabtagene autoleucel for specified adults with relapsed or refractory multiple myeloma after at least three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory drug. Product eligibility and access must be confirmed by an appropriately qualified treatment center within our network of featured international hospitals.
How does GPRC5D CAR-T differ from BCMA-targeted cellular therapy?
GPRC5D CAR-T targets G protein-coupled receptor class C group 5 member D, an antigen expressed on plasma cells independently of BCMA. GPRC5D CAR-T is being investigated as a distinct targeting approach, including in some patients whose disease has progressed after BCMA-directed therapy. While both therapies aim to eliminate malignant myeloma cells, it has a distinct adverse-effect profile that may include skin, nail, and taste-related effects requiring clinical monitoring and management.
Can GPRC5D CAR-T be considered for patients who have already relapsed after BCMA CAR-T?
Investigational GPRC5D CAR-T trials frequently evaluate patients who have experienced disease progression following prior BCMA-targeted therapies. Whether a patient is eligible depends entirely on institutional trial protocols, baseline organ fitness, and specific disease characteristics.
Is dual-target BCMA/GPRC5D CAR-T available outside of clinical trials in China?
No. Dual-target BCMA/GPRC5D constructs remain strictly investigational and are accessible solely through enrolled participation in clinical trials at participating academic medical centers. They are not commercially approved products.
What exact records are needed for a remote hospital review?
Hospitals commonly request bone marrow biopsy and aspirate reports, cytogenetic FISH panels, serial paraprotein measurements, a chronological record of prior systemic therapies and response durations, recent PET-CT or MRI scans, and baseline organ function labs. Exact requirements depend on the receiving institution.
Does a remote record review confirm eligibility for BCMA or GPRC5D CAR-T in China?
No. A remote record review may help a hospital determine whether further assessment is appropriate, but it does not guarantee trial enrollment, product access, or final admission. Eligibility must be determined by the receiving clinical team under the applicable product label or trial protocol.
Understanding the Administrative Pathway for International Patients
Accessing cross-border cellular therapy requires structured coordination across medical translation, hospital department routing, and logistics management. MedBridgeNZ coordinates administrative steps intended to help align international medical dossiers with the receiving institution’s stated submission requirements. You can learn more about our comprehensive approach on our international medical concierge services page.
Actionable Logistics Pathway & Assessment Options
Initial Case Intake & Record Formatting: Patients submit preliminary hematology records and access-controlled links for imaging scans. MedBridgeNZ compiles, translates, and formats these records into structured bilingual medical dossiers tailored for Chinese hospital intake requirements.
Specialist Routing & Assessment Options: Depending on the hospital, case, and available review channels, one of the following routes may be available:
Hospital Record Review: MedBridgeNZ can translate, format, and route the patient’s records to an appropriate hospital review channel where available. Any comments on possible eligibility, treatment options, costs, or scheduling are preliminary and are provided by the receiving clinical team. Final acceptance requires the hospital’s own assessment and does not result from MedBridgeNZ’s administrative review.
Hospital Video Consultation: Where offered by the receiving institution, MedBridgeNZ can coordinate a video consultation between the patient and the hospital’s clinical team. Consultation fees, availability, and any subsequent billing arrangements must be confirmed directly for the specific institution and case.
On-the-Ground Coordination: Upon confirmed institutional scheduling, MedBridgeNZ coordinates the agreed on-site administrative logistics. This includes navigating hospital registration systems, facilitating medical visa support documentation, providing bilingual accompaniment, and organizing local accommodation arrangements.
Patients seeking information about cross-border medical coordination, hematology record translation, or institutional review access may contact MedBridgeNZ to discuss available administrative pathways. Submit your initial inquiry via our Contact Us page, and our bilingual Patient Care Team aims to respond within one business day to explain the intake process.
Disclaimer: MedBridgeNZ acts strictly as an international medical concierge and logistics coordinator. We do not provide direct medical treatment, diagnosis, or clinical advice. This content is for informational purposes only and does not constitute medical guidance. Always consult your primary physician or treating oncologist before pursuing cross-border treatment options.
References
1. National Medical Products Administration. Equecabtagene Autoleucel Injection Approved with Conditions by China NMPA. https://english.nmpa.gov.cn/2023-06/30/c_940315.htm
2. CARsgen Therapeutics. NMPA Approves Zevorcabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma. https://www.carsgen.com/en/news/20240301/
3. National Medical Products Administration. Ciltacabtagene Autoleucel Injection Approved for Marketing by China NMPA. https://english.nmpa.gov.cn/2025-02/19/c_1073597.htm
4. Li C, et al. Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma: The FUMANBA-1 Nonrandomized Clinical Trial. https://pmc.ncbi.nlm.nih.gov/articles/PMC11544552/
5. Zhang M, et al. GPRC5D CAR T Cells (OriCAR-017) in Relapsed or Refractory Multiple Myeloma: POLARIS Phase 1 Trial. https://pubmed.ncbi.nlm.nih.gov/36725117/
6. Zhou D, et al. Anti-BCMA/GPRC5D Bispecific CAR T Cells in Relapsed or Refractory Multiple Myeloma. https://pubmed.ncbi.nlm.nih.gov/39059405/
7. Xia J, et al. Anti-GPRC5D CAR T-Cell Therapy After Progression Following Anti-BCMA CAR T-Cell Therapy. https://pubmed.ncbi.nlm.nih.gov/40228504/
8. International Myeloma Working Group. Consensus Guidelines for CAR T-Cell Therapy in Relapsed and Refractory Multiple Myeloma. https://pubmed.ncbi.nlm.nih.gov/38821074/
